These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2582782)

  • 21. Acute effect of erythropoietin on endothelin release in uremia.
    Nurol A; Bahattin A; Tolga K; Tekin A; Abdülkerim B
    Nephron; 1996; 72(4):728-9. PubMed ID: 8730461
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of recombinant erythropoietin on sexual function in hemodialysis patients.
    Schaefer RM; Kokot F; Heidland A
    Contrib Nephrol; 1989; 76():273-81; discussion 281-2. PubMed ID: 2684527
    [No Abstract]   [Full Text] [Related]  

  • 23. Neuroendocrinological effects of alcohol.
    Cicero TJ
    Annu Rev Med; 1981; 32():123-42. PubMed ID: 7013657
    [No Abstract]   [Full Text] [Related]  

  • 24. [Results of treating uremia anemia with human recombinant erythropoietin].
    Litwin M; Grenda R; Jelonek A
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):132-4. PubMed ID: 8090664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
    Fujita Y; Inoue S; Horiguchi S; Kuki A
    Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Iron poisoning as a risk in the treatment of nephrogenic anemia].
    Hansen BL; Pedersen FB
    Ugeskr Laeger; 1985 Aug; 147(35):2747-9. PubMed ID: 4071711
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of high doses of synthetic ACTH on the function of the hypothalamo-hypophyseal-adrenal cortex system].
    Walser A; Barthe P; Schär J
    Schweiz Med Wochenschr; 1968 Nov; 98(48):1892-5. PubMed ID: 4303138
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypothalamic-pituitary-adrenocortical suppression and recovery in renal transplant patients returning to maintenance dialysis.
    Rodger RS; Watson MJ; Sellars L; Wilkinson R; Ward MK; Kerr DN
    Q J Med; 1986 Nov; 61(235):1039-46. PubMed ID: 3310063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Erythropoietin treatment of dialysis patients].
    Stenver DI; Nielsen B
    Ugeskr Laeger; 1994 Apr; 156(17):2589-91. PubMed ID: 8016967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal changes in uremia.
    Bonomini V; Orsoni G; Stefoni S; Vangelista A
    Clin Nephrol; 1979 Jun; 11(6):275-80. PubMed ID: 477043
    [No Abstract]   [Full Text] [Related]  

  • 31. [Neutropenia and hypotension during treatment with recombinant human erythropoietin in refractory anemia with ring sideroblasts].
    Benzadón RJ; Gurfinkel EP
    Sangre (Barc); 1990 Jun; 35(3):238-9. PubMed ID: 2396173
    [No Abstract]   [Full Text] [Related]  

  • 32. [Study of various factors that could have an impact on the treatment with erythropoietin of hemodialysis anemia].
    Fernández-Gallego J; Ramos B; Ruiz A; Contreras J; Alvarez Bustos G; López de Novales E
    Nefrologia; 2000; 20(2):164-70. PubMed ID: 10853198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
    Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
    Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Follicle-stimulating gonadotropin function after neonatal treatment with chlorpromazine].
    Carraro A; Caviezel F; Colombo L
    Boll Soc Ital Biol Sper; 1970 Oct; 46(19):793-6. PubMed ID: 4933202
    [No Abstract]   [Full Text] [Related]  

  • 35. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of drugs on endocrine function.
    Vanderpump MP; Tunbridge WM
    Clin Endocrinol (Oxf); 1993 Oct; 39(4):389-97. PubMed ID: 8287564
    [No Abstract]   [Full Text] [Related]  

  • 37. [New pathogenetic views on renal anemia].
    Lamperi S
    Minerva Nefrol; 1982; 29(2):61-70. PubMed ID: 6752763
    [No Abstract]   [Full Text] [Related]  

  • 38. Alcohol and its effect on endocrine functioning.
    Van Thiel DH
    Alcohol Clin Exp Res; 1980 Jan; 4(1):44-9. PubMed ID: 6986814
    [No Abstract]   [Full Text] [Related]  

  • 39. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients.
    Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.